When will the DURAPREP patents expire, and when will generic DURAPREP be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Solventum	DURAPREP	iodine povacrylex; isopropyl alcohol	SPONGE;TOPICAL	021586-001	Sep 29, 2006		OTC	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Solventum	DURAPREP	iodine povacrylex; isopropyl alcohol	SPONGE;TOPICAL	021586-002	Sep 29, 2006		OTC	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 28, 2026

Duraprep is an iodine povacrylex/iodine antiseptic regimen used for pre-procedure skin preparation. Market attractiveness depends on (1) how Duraprep’s current FDA label supports sustained use in procedure settings, (2) whether substitute antiseptic regimens have displaced it, and (3) how much remaining IP protection blocks low-cost generics or “authorized” equivalents. Duraprep’s investment case is primarily an asset-life and competition-speed story rather than a high-risk R&D bet.

The sections below map FDA status, Orange Book/patent coverage, likely exclusivity drivers, litigation and generic entry risk pathways, and what to model for revenue, margin, and valuation under realistic commercialization scenarios.

What is Duraprep and what market fundamentals drive its value?

Duraprep is positioned for surgical and pre-procedure antisepsis. In commercial terms, the fundamental demand engine is hospital and ambulatory procedure volume, clinician formulary adoption, and procurement economics of antiseptic skin prep products.

What segments does Duraprep serve?

Core demand concentrates in:

Operating rooms and surgical suites
Emergency and procedural areas (burns, lacerations, wound prep)
Ambulatory surgical centers
Dental and minor procedure settings (where protocol-based skin antisepsis is used)

What are the practical buying criteria?

Hospital procurement for antiseptic prep products typically weights:

Clinical protocol compatibility (facility-specific order sets)
Ease of use and workflow impact
Skin tolerability and documented outcomes in label language
Packaging unit economics and supply reliability
Tendering and substitution rates among competing antiseptic regimens

What does this mean for investment modeling?

For Duraprep, the revenue curve generally correlates with:

Managed-care and hospital budget cycles
Substitution speed after payer or GPO-driven re-bids
Competitive intensity from alternative iodine products and non-iodine antiseptics
Potential entry of lower-cost equivalents if IP does not block substitution

Bottom line: Treat Duraprep as a commercial-life and defensibility case, not a platform-IP growth case.

What is the FDA regulatory status of Duraprep (and does it have Orange Book listings)?

Duraprep is an FDA-regulated antiseptic product. Investment due diligence requires checking whether Duraprep’s product is associated with an FDA Orange Book listing (drug substance/product patents and exclusivities) and whether it has active exclusivity protections that delay generic equivalents.

Key Orange Book questions for antiseptics

For products categorized outside classic small-molecule “generic” paradigms, Orange Book coverage may be sparse or absent. Where listings exist, the relevant questions are:

Is Duraprep listed as a drug product with patent numbers tied to the NDA?
Are any listed patents product formulation, method-of-use, or manufacturing related?
Is the exclusivity code present (for example, new chemical entity, new formulation, orphan, pediatric, or 505(b)(2) exclusivity)?

Why this matters for investor underwriting

If Duraprep is not Orange Book listed (or lacks unexpired patents), replacement risk accelerates:

Hospitals may substitute at re-bid cycles
Generics and “drop-in” equivalents can compete on price
Brand pricing power compresses without legal barriers

If Orange Book lists patents, you must model entry timing around:

Earliest expiration among composition/formulation and method-of-use patents
Any 180-day exclusivity tied to Paragraph IV filings (if applicable)
Pediatric exclusivity extensions or other statutory add-ons

What patents protect Duraprep, and how strong is the patent estate?

A patent estate that impacts durability typically includes:

Composition or formulation patents (active/vehicle, antiseptic regimen composition)
Manufacturing process patents (handling, dosing unit design, stability)
Method-of-use patents (clinical protocol specifics, sequence, application time)
Packaging patents (less common but sometimes present for multi-step regimens)

How to size “patent strength” for an antiseptic regimen

For investment purposes, score:

Number of unexpired patents by category (product vs method)
Remaining legal lives (years to last expiration)
Claim breadth indicators: whether patents cover a wide range of acceptable equivalents or narrow regimen specifics
Whether patents are asserted in litigation (enforcement signal)

What matters for competition speed

Even with patents, competitors can sometimes design around:

Changing vehicle components or concentration ranges
Altering application steps while staying within the label’s antisepsis intent
Using alternative actives if label and protocols allow

Investment implication: The relevant value driver is not “how many patents exist,” but how quickly design-arounds can produce a commercially substitutable product that bypasses claim coverage.

When does Duraprep lose exclusivity, and what are the likely generic entry risks?

The exclusivity and entry timeline determines whether the asset should be valued like:

A long-duration brand with delayed substitution, or
A mid-horizon cash flow that will compress around re-bid cycles

What timing levers typically control substitution?

Model these as separate “clocks”:

Patent expiration (last relevant expiration date across asserted or likely-to-be-relevant patents)
Any regulatory exclusivity period tied to the NDA (if present)
Litigation timeline and appeals (if Paragraph IV style challenges occur)
Practical market substitution timing after legal barriers lift

What generic entry “pathways” are most plausible for antiseptic products?

Depending on regulatory categorization, competitive entry can come via:

True generics (if the product supports generic approval pathways)
505(b)(2) amendments with reliance on literature or bridging studies
Authorized equivalents through labeling/compendial alignment
Contract manufacturing supply competition without legal challenge, if exclusivity is weak

Investment implication: If Duraprep has minimal unexpired IP or no Orange Book listing, assume substitution risk within the next tendering cycle after the closest legal barrier ends.

What formulations are protected for Duraprep, and can competitors design around?

For antiseptics, competitive differentiation often hinges on:

Active concentration and iodine availability profile
Polymer/vehicle chemistry and stability
Multi-step regimen mechanics (coverage and residue)
Shelf-life and unit dosing format

Formulation claim vulnerability indicators

Patent protection for a specific chemical regimen is often vulnerable if:

Claims are narrow to exact ratios and preparation steps
Allowed ranges exist in the claims that still permit easy substitution
Competitors can source similar ingredients that fall outside claim boundaries

Commercial substitutability indicators

Even where patents are narrow, hospitals may still adopt competing regimens if:

Clinical protocol endpoints are satisfied
Outcomes are similar in practice
Use is easier, less irritating, or faster

Investment implication: Expect pricing and share compression before the last patent expires if competing regimens meet protocol needs and outcompete on procurement.

What method-of-use patents could block label-compatible competition?

Method-of-use protection is common in therapeutics where the “how” matters. For antiseptics, potential method claims could include:

Specific application time before draping
Sequence requirements with other steps
Indications that tightly map to label language

How method-of-use claims affect entry

Method-of-use claims can slow competition if:

Competitors’ products cannot be used in the same way under their label
Competitors must deviate from clinical protocols to avoid infringement
Hospitals prefer to keep standardized protocols, so deviation is hard

What to watch in litigation or development plans

If competitors pursue development, they often:

Align label language with existing protocols
Avoid the claimed sequence or timing
Use formulation changes to reduce infringement risk

Investment implication: If method-of-use patents exist and claims are enforceable, valuation should discount earlier substitution and price in a longer brand protection window.

How does Duraprep compare with alternative antiseptic skin prep products?

Duraprep competes against a spectrum of antiseptic regimens used for skin preparation:

Iodine-based competitors
Chlorhexidine-based products (where used by protocol)
Alcohol-based antiseptics
Non-iodine alternatives depending on patient populations and facility protocols

What drives share between antiseptic brands

Share shifts are typically driven by:

Hospital formulary changes after annual tendering
Conversion from protocol updates
Clinical incident experience and safety perception
Unit dosing and workflow convenience

Investor relevance

A brand with strong protocol entrenchment can hold share even amid minor competition. A brand with weaker protocol lock-in can lose share quickly after bid cycles.

What patent litigation affects Duraprep, and what settlement signals matter?

For antiseptics, disputes can include:

Patent infringement allegations
Challenges to listed patents
Settlements that define “authorized launch” dates, design-around boundaries, or supply agreements

How to incorporate litigation into underwriting

Valuation should treat litigation as:

A schedule risk (delays to entry)
A claim-scope risk (strength of asserted patents)
A settlement framework risk (terms that allow early launch or partial carve-outs)

Settlement signals that predict market impact

Settlement terms to treat as high-signal:

Carve-out for specific concentrations or application steps
Permission to launch before patent expiration
Broad covenant not to sue that enables fast substitution
Geographic limitations or distribution channel restrictions

Investment implication: If there is active or recent litigation with settlement outcomes that allow early entry, the investment thesis should discount near-term brand durability.

What Paragraph IV-style challenges exist for Duraprep?

For small-molecule generics, Paragraph IV is standard. For antiseptics, the existence of Paragraph IV challenges depends on whether the product is approved under an NDA that supports generic application pathways.

What to model if challenges exist

If challengers file and assert invalidity or non-infringement:

Model a 30-month stay risk (if statutory triggers apply)
Model the likelihood of dismissal vs settlement vs trial outcomes
Model potential 180-day exclusivity benefits if applicable to the filing pathway

Investment implication: If Duraprep is not subject to Paragraph IV-style frameworks, competition may instead be driven by regulatory pathways that do not create a clear statutory stay.

What is the commercial landscape for Duraprep (pricing, share, and margin drivers)?

Antiseptic products typically have:

Procurement-driven pricing dynamics
Margin pressure from competitive bidding
Cost structure influenced by unit packaging formats and supply contracts

What to model for revenue durability

Model:

Average realized price and discount rate trends
Share stability across hospital systems
Volume sensitivity to procedure mix and occupancy
Contract renewals and switching costs

What to model for margin

Margin hinges on:

Manufacturing scale and yields
Input costs for iodine/vehicle components
Packaging cost and unit dosing engineering
Distributor and GPO rebate structures

Investment implication: If patent protection is weak, revenue volatility increases around contract cycles, making cash flow duration the key underwriting variable.

How does Duraprep compare to other antiseptic brands on patent and regulatory defensibility?

Use a defensibility matrix to compare antiseptic rivals on:

Whether they have active Orange Book listings tied to the regimen
Number and category of unexpired patents
Presence of litigation and settlement history
Label scope that constrains “off-label” substitution

Defensibility matrix (template for investment committee)

Company / Product	Active Orange Book?	Unexpired Patents by Category	Litigation Status	Expected Substitution Speed
Duraprep	(requires Orange Book check)	Product / Method / Process	(requires docket check)	(model by remaining lives)
Competitor A
Competitor B

Investment implication: The highest-return scenario usually corresponds to a product with (1) a dense unexpired patent estate and (2) protocol lock-in that slows switching.

What investment scenarios fit Duraprep based on IP and competition speed?

Without asserting specific expiration dates or listing counts, the scenario framework is:

Base case: moderate durability

Brand holds share through ongoing contracts
IP does not immediately block substitution, but price compression is gradual
Generic/equivalent entry occurs later or is limited by label/protocol compatibility

Downside case: fast substitution

Weak or expiring IP removes barriers
Competitive regimens meet protocol and perform similarly
Procurement-driven switching reduces share quickly, with rapid price compression

Upside case: delayed entry and stronger than expected enforcement

Patent estate remains enforceable for longer horizons
Litigation outcomes delay or narrow generic equivalents
Hospital systems resist switching due to protocol and safety preferences

Investment implication: The distribution of outcomes is skewed by the existence and strength of enforceable IP and the substitutability of competing antiseptics under facility protocols.

Key Takeaways

Duraprep’s investment case is governed by exclusivity and enforceable IP durability plus procurement-driven substitution dynamics.
The fastest predictor of revenue compression is whether Duraprep has unexpired Orange Book-linked patents that legally constrain equivalents and whether litigation or settlements extend launch timelines.
Under weak IP, model rapid share loss around re-bid cycles and pricing compression consistent with antiseptic tender markets.
Under strong enforceable IP and protocol lock-in, model longer cash flow duration and lower substitution speed, supporting a higher valuation multiple.

FAQs

1) Is Duraprep an Orange Book listed drug, and what does that imply for generic competition?
2) What kinds of patent claims (formulation vs method-of-use) are most likely to matter for antiseptic skin prep regimens like Duraprep?
3) If Duraprep’s patents expire, how quickly do hospitals typically switch antiseptic products after tender rebids?
4) Do antiseptic products face Paragraph IV-style challenges, or do competitors usually enter through other regulatory pathways?
5) What litigation settlement terms most strongly predict how soon equivalents can launch and be adopted by hospital formularies?

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
U.S. Food and Drug Administration. Drug Approval Packages and Labeling. FDA.
U.S. Court of Appeals for the Federal Circuit and U.S. District Courts. Patent litigation dockets (public records).

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for DURAPREP